Hormone replacement therapy and risk of lymphomas and myelomas

European Journal of Cancer Prevention

Volumn 13, Issue 4, 2004, Pages 349-351

  Altieri, A ^a   Gallus, S ^a   Franceschi, S ^b   Fernandez, E ^c   Talamini, R ^d   La Vecchia, C ^a,e  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Case control studies; Hodgkin's Disease; Hormone replacement therapy; Multiple myeloma; Non Hodgkin's lymphoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HISTOLOGY; HODGKIN DISEASE; HORMONE SUBSTITUTION; HOSPITAL ADMISSION; HUMAN; ITALY; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

AGE DISTRIBUTION; AGED; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; FEMALE; HODGKIN DISEASE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; ITALY; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MULTIPLE MYELOMA; ODDS RATIO; POSTMENOPAUSE; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE;

EID: 4143070582     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cej.0000136573.16740.9c     Document Type: Article

References (18)

1. Anderson GL, Judd HL, Kaunitz AM, et al. (2003). Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 290: 1739-1748.
2. Beral V, Banks E, Reeves G (2002). Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360: 942-944.
3. Bernstein L, Ross RK (1992). Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Res 52: 5510s-5515s.
4. Bosetti C, Tavani A, Negri E, et al. (2001). Reliability of data on medical conditions, menstrual and reproductive history provided by hospital controls. J Clin Epidemiol 54: 902-906.
5. Cerhan JR, Vachon CM, Habermann TM, et al. (2002). Hormone replacement therapy and risk of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev 11: 1466-1471.
6. Chiaffarino F, Parazzini F, La Vecchia C, et al. (1999). Correlates of hormone replacement therapy use in Italian women, 1992-1996. Maturitas 33: 107-115.
7. Fernandez E, Gallus S, Bosetti C, et al. (2003). Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 105: 408-412.
8. Forsberg JG (1984). Short-term and long-term effects of estrogen on lymphoid tissues and lymphoid cells with some remarks on the significance for carcinogenesis. Arch Toxicol 55: 79-90.
9. Franceschi S, Serraino D, Bidoli E, et al. (1989). The epidemiology of non-Hodgkin's lymphoma in the North-east of Italy: a hospital-based case-control study. Leuk Res 13: 465-472.
10. Glaser SL (1994). Reproductive factors in Hodgkin's disease in women: a review. Am J Epidemiol 139: 237-246.
11. IARC (1999). Monographs on the Evaluation of Carcinogenic Risks to Humans. Hormonal Contraception and Post-menopausal Hormonal Therapy, Vol 72. IARC, Lyon.
12. La Vecchia C, Brinton LA, McTiernan A (2001). Menopause, hormone replacement therapy and cancer. Maturitas 39: 97-115.
13. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
14. Medina KL, Strasser A, Kincade PW (2000). Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. Blood 95: 2059-2067.
15. Nelson RA, Levine AM, Bernstein L (2001). Reproductive factors and risk of intermediate- or high-grade B-Cell non-Hodgkin's lymphoma in women. J Clin Oncol 19: 1381-1387.
16. Prihartono N, Palmer JR, Louik C, et al. (2000). A case-control study of use of postmenopausal female hormone supplements in relation to the risk of large bowel cancer. Cancer Epidemiol Biomarkers Prev 9: 443-447.
17. Stahlberg C, Pedersen AT, Lynge E, et al. (2004). Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 109: 721-727.
18. Tavani A, Pregnolato A, La Vecchia C, et al. (1997). A case-control study of reproductive factors and risk of lymphomas and myelomas. Leuk Res 21: 885-888.